Researchers create new synthetic heparin

Sep 21, 2007

Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms.

Led by Jian Liu, Ph.D., scientists in the UNC School of Pharmacy discovered that they could remove a complex element from the heparin molecule without altering the drug’s function. The component, a single sugar called iduronic acid, is difficult to replicate and was long thought to be an important contributor to heparin’s function as an anticoagulant, Liu said.

“We proved we don’t really need that structure for the anticoagulant effect,” Liu said. “By eliminating the iduronic acid unit, we were able to reduce the structural complexity of the heparin molecule by approximately 50 percent.”

Their findings were published in the Sept. 24, 2007, issue of the journal Chemistry & Biology. The study was supported by a grant from the National Institutes of Health.

Heparin is most commonly used to prevent clots from forming and restricting the flow of blood during and after procedures such as kidney dialysis, heart-bypass surgery, stent implantation and knee and hip replacement. The annual worldwide sales of heparin are estimated at $3 billion.

Heparin is a natural substance that is extracted from animal tissue, chiefly from cows and pigs. Outbreaks of diseases among livestock can interfere with production of the drug, driving up prices and tightening supplies.

“Synthesizing heparin, rather than extracting it from animals, gives us more control over its anticoagulant properties and creates a purer, safer, more reliable drug,” Liu said.

Currently, synthetic forms of heparin are difficult to produce in large quantities because of the drug’s complexity, resulting in expensive therapies that are not widely used, Liu said.

The simpler structure of Recomparin is likely to be easier to produce than other forms of synthetic heparin, Liu says. It is also expected to reduce dangerous side effects, such as uncontrolled bleeding, while providing the same benefits as naturally derived heparin.

The next step for Recomparin will be to find a company to license the drug and begin the process of getting Food and Drug Administration approval.

Source: University of North Carolina at Chapel Hill

Explore further: FDA approves tough-to-abuse formulation of oxycodone

add to favorites email to friend print save as pdf

Related Stories

Lives and deaths of sibling stars

11 minutes ago

This beautiful star cluster, NGC 3293, is found 8000 light-years from Earth in the constellation of Carina (The Keel). This cluster was first spotted by the French astronomer Nicolas-Louis de Lacaille in ...

Telerobotics puts robot power at your fingertips

11 minutes ago

At the Smart America Expo in Washington, D.C., in June, scientists showed off cyber-dogs and disaster drones, smart grids and smart healthcare systems, all intended to address some of the most pressing challenges ...

Ultra high definition TVs boost LG Display profit

1 minute ago

(AP)—LG Display Co. said profit for the April-June quarter more than doubled as a stronger won reduced the value of its foreign debt and the World Cup boosted demand for ultra-high-definition TVs.

Recommended for you

FDA approves tough-to-abuse formulation of oxycodone

20 minutes ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

32 minutes ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

18 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

23 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

23 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

User comments : 0